Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis - PubMed (original) (raw)
Meta-Analysis
doi: 10.2217/fon.14.290. Epub 2014 Dec 5.
Affiliations
- PMID: 25478720
- DOI: 10.2217/fon.14.290
Meta-Analysis
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis
Sanjay Popat et al. Future Oncol. 2015.
Abstract
Background: Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. No published trials have previously compared nintedanib plus docetaxel with agents – other than docetaxel – that are approved second-line treatments for non-small-cell lung cancer.
Methods: The relative efficacy of nintedanib plus docetaxel versus second-line agents was evaluated by conducting a network meta-analysis of progression-free survival and overall survival.
Results: Nine suitable studies were identified. The estimated probability of nintedanib plus docetaxel being the best treatment with regard to overall survival was 70% (versus 16% for pemetrexed, 10% for docetaxel and 3% for erlotinib). Results for progression-free survival were similar.
Conclusion: In patients with advanced non-small-cell lung cancer of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group.
Keywords: NSCLC; adenocarcinoma; chemotherapy; nintedanib; second-line treatment.
Similar articles
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S; LUME-Lung 1 Study Group. Reck M, et al. Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9. Lancet Oncol. 2014. PMID: 24411639 Clinical Trial. - Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S. Nishiyama A, et al. Lung Cancer. 2015 Sep;89(3):301-5. doi: 10.1016/j.lungcan.2015.06.017. Epub 2015 Jun 25. Lung Cancer. 2015. PMID: 26141215 - Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Griebsch I, Palmer M, Reck M; LUME-Lung 1 Study Group. Novello S, et al. Eur J Cancer. 2015 Feb;51(3):317-26. doi: 10.1016/j.ejca.2014.11.015. Epub 2014 Dec 17. Eur J Cancer. 2015. PMID: 25534294 Clinical Trial. - Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
Reck M, Heigener D, Reinmuth N. Reck M, et al. Expert Rev Clin Pharmacol. 2014 Sep;7(5):579-90. doi: 10.1586/17512433.2014.945430. Expert Rev Clin Pharmacol. 2014. PMID: 25119062 Review.
Cited by
- Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics.
De Vlieghere E, Verset L, Demetter P, Bracke M, De Wever O. De Vlieghere E, et al. Virchows Arch. 2015 Oct;467(4):367-82. doi: 10.1007/s00428-015-1818-4. Epub 2015 Aug 11. Virchows Arch. 2015. PMID: 26259962 Review. - Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Alhadeethi A, Adel Awwad S, Abed M, Amin AM, Aboelkhier MM, Yassin MNA, Morsi MH, Kashbour MO. Alhadeethi A, et al. Cureus. 2024 Feb 7;16(2):e53812. doi: 10.7759/cureus.53812. eCollection 2024 Feb. Cureus. 2024. PMID: 38465177 Free PMC article. Review. - Fibroblasts, an inconspicuous but essential player in colon cancer development and progression.
Mukaida N, Sasaki S. Mukaida N, et al. World J Gastroenterol. 2016 Jun 21;22(23):5301-16. doi: 10.3748/wjg.v22.i23.5301. World J Gastroenterol. 2016. PMID: 27340347 Free PMC article. Review. - Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
Vickers AD, Winfree KB, Cuyun Carter G, Kiiskinen U, Jen MH, Stull D, Kaye JA, Carbone DP. Vickers AD, et al. BMC Cancer. 2019 Apr 15;19(1):353. doi: 10.1186/s12885-019-5569-5. BMC Cancer. 2019. PMID: 30987609 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical